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Abstract
The study of somatic genetic alterations in tumors contributes to the understanding and management of cancer. Genetic
alterations, such us copy number or copy neutral changes, generate allelic imbalances (AIs) that can be determined using
polymorphic markers. Here we report the development of a simple set of calculations for analyzing microsatellite multiplex
PCR data from control-tumor pairs that allows us to obtain accurate information not only regarding the AI status of tumors,
but also the percentage of tumor-infiltrating normal cells, the locus copy-number status and the mechanism involved in AI.
We validated this new approach by re-analyzing a set of Neurofibromatosis type 1-associated dermal neurofibromas and
comparing newly generated data with results obtained for the same tumors in a previous study using MLPA, Paralog Ratio
Analysis and SNP-array techniques. Microsatellite multiplex PCR analysis (MMPA) should be particularly useful for
analyzing specific regions of the genome containing tumor suppressor genes and also for determining the percentage of
infiltrating normal cells within tumors allowing them to be sorted before they are analyzed by more expensive techniques.
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Introduction
Cancer development and progression is partly driven by the
acquisition of somatic genetic alterations [1]. Both DNA copy-
number changes and copy-neutral events have traditionally been
identified by detecting the presence of allelic imbalances (AIs).
These are significant deviations from the 1:1 allelic ratio of any
heterozygous marker in a diploid cell, which are often reported as
a loss of heterozygosity (LOH) when analyzing tumor-control
tissue DNA pairs. Different techniques have been used to
specifically detect copy-number changes in tumor DNA, such as
semi-quantitative [2] or quantitative [3] PCR reactions, Multiplex
Ligation-dependent Probe Amplification (MLPA) [4], Multiplex
Amplicon Quantification (MAQ) [5] or array-CGH [6]. However,
these techniques are not able to detect copy-neutral events, such as
homologous recombination, which often reduce mutated tumor
suppressor genes to homozygosity [7]. Fluorescent multiplex
microsatellite PCR has been developed, semi-automatized and
used in tumor AI analysis for a long time [8], and is still used now
[9]. Determining the quotient between tumor-control tissue allelic
ratios for a given heterozygous marker identifies AI. Guidelines on
how to score and interpret AI analysis using microsatellite
multiplex have been developed (see for instance [10]) as well as
methodological modifications and statistical refinement (see for
instance [11]). However, in order to differentiate whether an AI in
a given locus is caused by a loss of DNA material or by a copy-
neutral event, the use of an additional technique is required to
determine the copy-number status of the locus. In addition, one of
the problems of genetic analysis of tumors is the presence of high
percentages of normal cells infiltrating the tumors. Since the
development of microsatellite PCR for tumor AI analysis the
presence of normal (non-AI) cells has been identified by the
remaining signal of the lost allele, and grossly estimated by a
simple allele ratio. This approximation is quite accurate in the case
of an AI caused by a true loss of DNA material but it is not a good
method in the case of copy-neutral events.
Today SNP-array analysis is the only single technique that can
provide high resolution genome scale information on allele-specific
copy-number, map and evaluate copy-neutral LOH, and accu-
rately model the fractions of normal and tumor cells in tumor
samples [12]. However, SNP-array analysis is not the preferred
technique when analyzing just a few loci (e.g. to evaluate the status
of specific tumor suppressor gene locus) or when performing a
screening of many samples to make a tumor triage for further
analysis, because of the high cost.
In this study we describe how, by applying simple calculations to
an analysis of a microsatellite multiplex PCR (here referred to as
MMPA), it is possible to obtain accurate information regarding not
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only the allelic imbalance status, but also the percentage of tumor-
infiltrating normal cells and the locus copy-number status. This
allows us to infer which mechanism is generating the AI: copy-loss,
copy-neutral or amplification. To evaluate the MMPA perfor-
mance we analyzed microsatellite data from Neurofibromatosis
Type 1-associated dermal neurofibromas. These tumors are
difficult to genetically analyze due to their high degree of cellular
heterogeneity. 25% of neurofibromas exhibit AI in the NF1 locus
[13]. Of these, in 62% of the cases AI is produced by a copy-
neutral event (homologous recombination in all of them) and in
38% it is produced by copy-number loss (deletion in all cases). We
applied the MMPA calculations to a set of dermal neurofibromas
already characterized in a previous study [13]. We compared the
newly developed calculations in this report, with previous data
obtained by applying MLPA, Paralog Ratio Analysis (PRA) and
SNP-array in the same tumor samples.
Results
MMPA set up
We used a previously designed microsatellite multiplex PCR
[13] to set up new reaction conditions and perform quality
controls that allowed us to perform MMPA calculations proposed
in this work (Table S1 and Figure S1, S2, S3, S4, S5, S6 and S8).
Proportionality between co-amplified amplicons. The
MMPA calculations proposed here rely on comparing co-
amplified microsatellites of control-tumor pairs. Proportionality
between co-amplified amplicons must be maintained. In the
MMPA set up shown here 22 cycles of PCR amplification ensured
an adequate yield of each PCR amplicon while still maintaining an
exponential reaction phase, guaranteeing proportionality among
the different co-amplified amplicons for each independent
multiplex PCR reaction (Figure S1).
Constant of proportionality (Km) among sample pairs and
variation analysis. Control-tumor independent multiplex
PCR reactions can be compared and a constant of proportionality
(K) can be calculated for each heterozygous microsatellite using
peak height values (Figure 1a). Each K should be approximately
the same for the different co-amplified amplicons within the
MMPA reaction. The mean of the different microsatellite Ks (Km)
reflects the constant of proportionality between the control-tumor
compared reactions and can be calculated using either known pre-
established control microsatellite markers within the MMPA
reaction or by only taking into account those microsatellite
markers that show no allelic imbalance (AI) in the tumor sample
(see below). Variation of Km affects the accuracy and sensitivity of
proposed MMPA calculations and the coefficient of variation (CV)
of Km is used as a quality control (Figure 1a). Km variation should
be set up and controlled for each MMPA before analyzing and
comparing control-tumor pairs and we propose CV#0.15 (Figures
S2a and S2b).
Detection of allelic imbalances. AI analysis was based in
the expression QAI [14] that represents the quotient between the
tumor allelic ratio of a given heterozygous microsatellite marker
within the MMPA reaction, and the allelic ratio for the same
marker in the control sample [15]. A microsatellite marker was
considered to show AI if, after calculating QAI, there was a
difference between ratios equal or greater than 0.2. This threshold
was established after studying QAI variation caused by method-
ological errors (Figure S3).
Expected allele peak height values and comparison of
observed vs. expected allele peak heights. MMPA calcula-
tions are based in the comparison between the observed peak
height values of a heterozygous microsatellite marker (peakobs)
with the hypothetical situation (expected peak heights, peakexp) in
which there is no AI for that microsatellite marker. Peakexp in the
tumor is calculated by multiplying Km by the allele peak height
value of the relative microsatellite in the control sample
(peakC)(Figure 1b):
Peakexp~peakC:Km
Allele peak heights of a microsatellite with AI will depend on the
number of copies of that allele in AI-cells and the percentage of
AI-cells within the tumor. Depending on the mechanism
generating AI (Figure 2) peakobs values will increase, decrease or
will be equal to peakexp values. By comparing peakobs and peakexp
values of a given tumor microsatellite with AI, it can be
ascertained which allele has lost a locus dosage (observed peak
lower than expected), has an equal locus dosage (observed peak
equal to the expected) or has a higher locus dosage (observed peak
higher than expected) compared to the allelic status of the control
sample pair of that microsatellite marker (Figure 2). To perform
this comparison, an interval of peakexp values is calculated by
taking into account an empirically determined variation value (e)
that is applied to Km:
Peakexp +e½ ~peakC: Km+eð Þ
e [e= Km?W] depends and is intrinsic to each MMPA reaction set
up and takes into account an upper limit threshold (W) established
by analyzing individual deviations of K vs. Km for every
microsatellite marker used in the MMPA reaction (see Figure S2b).
Calculating the percentage of cells exhibiting allelic
imbalance from AI-markers caused by copy-loss or copy-
neutral events
MMPA can be used to estimate the percentage of cells within
tumors that carry an AI in an interrogated heterozygous marker
locus. This is possible only in the cases where AI is produced by
either copy-loss or copy-neutral events, and assuming a simple
model in which tumors are mainly composed of two populations of
cells: normal 2n cells and AI-cells. Once AI is identified, a
comparison of peakobs and peakexp values is performed. In the case
of AI due to copy-loss and copy-neutral events, one of the observed
alleles will show a reduced peak height signal compared to the
expected peak height (Peak 2exp in Figures 2b and 2c and in
Figure 3), and only this allele will be used to calculate the
percentage of non-AI cells present in the tumor sample (Figure 3).
The difference between the expected and observed peak heights is
directly proportional to the percentage of cells bearing AI for this
allele, since the observed peak height signal is only produced by





For simplicity, the calculation of non-AI cells present in a tumor
will be performed using a single Km value, rather than an interval
of values.
Calculating locus copy-number in cells showing allelic
imbalance from AI-markers caused by copy-loss or copy-
neutral events
MMPA analysis can provide information on whether each allele
of an AI-locus has one, two or more than two copies. Considering
Rapid Genetic Analysis of Tumor Heterogeneity
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the same AI-marker, the allele not used for calculating the
percentage of non-AI cells is used to determine both the number of
copies of that allele and the mechanism generating AI (peak 1obs in
Figures 2b and 2c, and in Figure 3). Using the percentage of AI/
non-AI cells previously calculated and taking into account gene
dosages that will result from the different mechanisms generating
AI, expected peak height ratios are calculated. e will be used to
generate interval values, considering two scenarios:
Copy-loss clð Þ
Peakexp cl ð+eÞ~ peakexp +eð Þ:% non-AI cells
 
z
peakexp +eð Þ:% AI cells
 
Copy-neutral cnð Þ change
Peakexp cn +eð Þ~ peakexp +eð Þ:% non-AI cells
 
z
peakexp +eð Þ:2:% AI cells
 
Peakobs values will fit into one of the two intervals of peakexp,
indicating the locus copy-number status and the mechanism
generating AI. In the case peakobs value does not fit any of the two
expected intervals, the value should be considered out of range
(OOR) and the corresponding microsatellite cannot be used for
MMPA calculations. In the case that the two copies of a given
locus were lost (e.g. nullosomy) or gained (e.g. tetrasomy) AI would
not be detected. However, in these cases affected microsatellites
would show K values substantially different from K values of other
non-AI microsatellites.
A low degree of variation in Km for each MMPA reaction is
critical for a correct assessment of both the percentage of AI/non-
AI cells in tumors and allele copy-number (see Figure S4, S5 and
S8).
Analysis of other mechanisms generating AI in
microsatellites
We have described so far the use of MMPA calculations for
detecting copy-loss and copy-neutral events, but AI can also be
due to copy-number gains of one allele or by the gain of a different
number of copies of each allele (see Figure 2d as an example). In
fact, equations described to obtain ‘‘peakexp cl’’ or ‘‘peakexp cn’’
could be adapted to calculate any gain in locus copy-number
generating AI (see Fig. S6). When analyzing AIs produced by
copy-number gains, information regarding the percentage of non-
AI cells will not be produced. However, in the context of a specific
tumor and under the assumption that all genetic alterations
causing AI are present in the same tumor cell population,
information on the percentage of normal cells present in that
tumor could be obtained from other AI-markers if AI is caused by
copy-loss or copy-neutral events. In the case that one or more
extra copies of one allele is gained, peakobs of that allele will be
greater than the peakexp, while the remaining allele will be equal.
In the case both alleles of an AI-marker gain extra copies but in
different numbers, both peakobs will be greater than the respective
peakexp (see Fig. S6 and S7).
Figure 1. Constant of proportionality calculation and expected peak height estimation. a) Example illustrating how the average of the
proportionality constant (Km) between two microsatellite multiplex PCR reactions that compare control and tumor paired samples, is calculated.
Microsatellite electropherograms are shown. Control microsatellites are determined using QAI values (see text). Each microsatellite peak has a
constant of proportionality (K). Km is the average of all individual Ks from control microsatellites. The coefficient of variation (CV) of Km is calculated as
a quality control parameter (see text for details). b) Example of the calculation of expected peak heights (in the case 100% of the cells were non-AI) of
a query microsatellite D with hypothetical allelic imbalance (AI) by using Km between control and tumor paired samples. Black line, observed peak
heights (obs); dashed line, expected peak heights (exp).
doi:10.1371/journal.pone.0042682.g001
Rapid Genetic Analysis of Tumor Heterogeneity
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Applying MMPA analysis to determine the NF1 locus
status in neurofibromas
Our group previously characterized a large set of neurofibromas
for the presence/absence of AI in the NF1 region by applying
microsatellite analysis [13]. In the same study, the copy-number
status of the same region was determined by either MLPA, PRA or
SNP-array analysis [13]. After developing the MMPA calculations
presented here, we re-analyzed a set of 29 dermal neurofibromas
with the newly established microsatellite multiplex PCR conditions
and obtained data regarding the percentage of non-AI cells within
Figure 2. Peakobs vs. peakexp comparison for 1 heterozygous microsatellite in the analysis of AIs generated by different mutational
mechanisms. Dashed line circles represent sample tissues (normal or tumor) and solid line circles represent types of genetically distinct cells within
tissues. Blue and orange solid lines within chromosome-representing boxes indicate alleles of a heterozygous microsatellite marker. Solid color peaks
represent allele peak heights obtained from microsatellite electropherograms after a theoretical MMPA. Dashed color peaks indicate expected peak
heights in the case that 100% of the cells were non-AI, with the interval of peak height values indicated. Underneath allele peaks there is a short
explanation of the source of peak height intensities regarding the number of amplified alleles according to the percentage of AI and non-AI cells. The
Obs/Exp peak comparisons are also shown for the different mechanisms: a) Sample with no AI; b) Tumor sample with AI due to a copy-number loss; c)
Tumor sample with AI due to a copy-neutral event; d) Tumor sample with AI due to a copy-number gain. Note that identical AI values for a given
microsatellite in examples b and c will reflect distinct percentages of AI-cells within tumor samples.
doi:10.1371/journal.pone.0042682.g002
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these tumors and the NF1 locus copy-number. We compared the
new MMPA generated data with that previously obtained in [13]
for these 29 neurofibromas (Tables 1 and 2).
In 26 out of 29 neurofibromas MMPA calculations correctly
determined locus copy-number and AI-mechanism, considering all
informative microsatellites (Table 1). In addition, AI-mechanism
was correctly determined in all neurofibromas, considering that
they had at least 3 informative AI-microsatellites (27/29), and
taking into account a correct result when at least 60% of all
informative microsatellites were indicating the correct mechanism
(Table 1). Overall 144 microsatellites showing AI were identified
in these 29 neurofibromas: AI-mechanism was correctly deter-
mined after MMPA in 116 (80.5%); 25 (17.4%) were out of range
(OOR) meaning that the peakobs value was not fitting within any
of the expected intervals; and only 3 (2.1%) were incorrectly
determined (Table 1). We included samples P009-1N and P102-
4N (marked with an * in Table 1) in the analysis. These tumor
samples contained high percentages of non-AI cells, making copy-
number analysis impossible by MLPA, as shown in Garcia-Linares
et al. (2011). However, they were considered to bear a deletion in
the NF1 locus, based in the similarity with other tumor samples
bearing the same localized AI (only affecting the NF1 gene and
surrounding regions). MMPA calculations in these samples
determined a deletion, supporting that this might be the actual
mechanism generating AIs in these tumors. Copy-number
ascertainment by MMPA calculations was possible due to the
higher sensitivity of this technique when dealing with tumors
containing high percentages of non-AI cells (Figure S5 and S8).
Regarding the presence of normal cells within tumors, we
calculated the percentage of AI/non-AI cells for 9 neurofibromas
using previously generated SNP-array data [13] by applying the
GPHMM algorithm [16]. We compared these data with the
percentages obtained for the same tumors by applying MMPA
calculations (Table 2). The results showed a good agreement
between both techniques since, for all tumor samples but one, the
calculated percentages of non-AI cells present in neurofibromas
did not differ more than 8%.
In order to facilitate the calculations of the MMPA assay, we
developed an automated analysis script that outputs the different
parameters of an MMPA reaction together with the different
calculations explained above (see Material and Methods; Script
S1). This script is also freely downloadable at http://www.imppc.
org/research-activities/genetic-variation-and-cancer/mmpa.html
and can be easily customized to any MMPA design.
Discussion
In this study we present a set of simple calculations (MMPA)
applied to a microsatellite multiplex PCR to gain information on
the percentage of normal cells present in a tumor, the copy-
number status of specific alleles of heterozygous loci showing AI
and the mechanisms that generate these AIs. Previously, to obtain
the same type of tumor genetic information, the use of
microsatellite PCR had to be complemented with additional
techniques. A global view of this new approach is summarized in
Figure S7.
All information that can be obtained by applying an MMPA is
based on the use of a constant of proportionality (Km) between a
multiplex PCR reaction of a tumor DNA and its matching control
pair. Thus, one of the key factors when using MMPA calculations
is to design and set up a robust multiplex reaction controlling all
aspects that affect Km to minimize variation in its value and in that
way minimize the errors in the estimation of expected peak heights
(see supplementary information). DNA quality is also an important
aspect for the correct performance of MMPA, as it could affect
DNA amplification and increase Km dispersion. Bad quality DNA
can make MMPA calculations impossible. In addition, it is
important to precisely quantify and always analyze the same
amount of DNA for all samples. K values from microsatellites with
no AI considerably different from 1 could indicate genetic
alterations causing copy-number gains or losses without generating
Figure 3. Calculating the percentage of non-AI cells and the locus copy-number of AI-cells from markers with allelic imbalance
caused by copy-loss or copy-neutral events. Schematic view of the different use of both microsatellite alleles comparing observed vs. expected
allele peak heights, concerning the calculation of the percentage of non-AI cells and the locus copy-number determination. Solid color peaks
represent allele peak heights obtained from microsatellite electropherograms after a theoretical MMPA. Dashed color peaks indicate expected peak
heights in the case 100% of the cells were non-AI. cl, copy-loss; cn, copy-neutral.
doi:10.1371/journal.pone.0042682.g003
Rapid Genetic Analysis of Tumor Heterogeneity
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allelic imbalances, as happens in cases where the two copies of a
given locus were lost (e.g. nullosomy) or gained (e.g. tetrasomy).
Since Km is calculated from control microsatellites, it is desirable
to have at least three informative control microsatellites in the
MMPA. Previous knowledge about the degree of genetic instability
and the recurrence of altered and non-altered genomic regions
would facilitate the inclusion of pre-established control markers in
the MMPA design. This should not be a problem when analyzing
specific genomic regions in tumors with a low or intermediate
degree of recurrent copy-number alterations. However, in tumors
with a highly altered genome, it will not be possible to determine
upfront which markers could be used as control microsatellites,
and only after doing MMPA calculations could those not
exhibiting AI (and Ks close to 1) be used as control markers.
In addition, during the MMPA analysis, special care should be
paid to heterozygous dinucleotide microsatellites when both alleles
only differ in one repeat (2 bp). In these cases, the slippage of the
DNA polymerase during PCR amplification can hamper the
correct analysis of peak height values of smaller alleles, thus
affecting the calculations of copy-number and percentage of AI-
cells in markers showing AI. In the MMPA setup presented here,
we decided not to use heterozygous microsatellite markers with a
difference in length of only 2 bp for the MMPA calculations.
However in the case that these microsatellites were required, a
correction on the peak height values of the smaller alleles could be
applied [10].
The interpretation of the information produced by an MMPA is
based on a simple model in which tumors are composed of two cell
populations: normal 2n cells and cells containing allelic imbalanc-
Table 1. MMPA validation of the NF1 locus copy-number.










P001-1N Two copies 6/7 1 OOR Two copies
P009-1N One copy 4/4 *
P011-16N Two copies 4/5 1 OOR Two copies Two copies
P022-19N Two copies 3/5 2 OOR Two copies
P022-21N Two copies 1/6 5 OOR Two copies
P023-14N Two copies 6/8 2 OOR Two copies Two copies
P023-6N One copy 3/4 1 RH One copy One copy One copy
P023-97N One copy 3/5 2 OOR One copy One copy One copy
P030-2N Two copies 4/5 1 OOR Two copies
P039-1N One copy 4/4 One copy One copy
P047-1N Two copies 4/5 1 OOR Two copies
P054-1N Two copies 6/6 Two copies
P062-11N One copy 2/2 One copy
P079-1N One copy 3/3 One copy One copy
P081-1N One copy 5/5 One copy
P082-6N One copy 5/5 One copy One copy
P090-3N One copy 3/3 One copy One copy
P095-1N One copy 2/3 1 OOR One copy One copy
P102-3N One copy 4/5 1 OOR One copy
P102-4N One copy 1/2 1 OOR *
P102-5N Two copies 8/9 1 OOR Two copies
P102-18N Two copies 9/9 Two copies Two copies Two copies
P103-5N Two copies 5/5 Two copies Two copies Two copies
P103-21N Two copies 4/6 2 OOR Two copies Two copies
P109-1N Two copies 4/5 1 Del Two copies
P109-5N Two copies 3/5 1 OOR, 1 Del Two copies
P109-6N Two copies 4/4 Two copies
P109-7N Two copies 3/4 1 OOR Two copies
P112-4N Two copies 3/5 2 OOR Two copies
*see text for details.
Analysis of the copy number status of the NF1 locus in 29 neurofibromas using newly developed MMPA calculations and comparison with previous data obtained for
the same tumors using MLPA, PRA and SNP-array techniques (13).
doi:10.1371/journal.pone.0042682.t001
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es. A limitation of the MMPA in relation to the ascertainment of
the percentage of normal cells present within a tumor is that this
information can only be obtained from microsatellite markers
showing AI due to copy-number loss or copy-neutral events. Then,
this information can be used to analyze microsatellite markers
showing AI due to copy-number gains present in the same tumor,
but again, only under the assumption that all genetic alterations
causing AI are present in the same population of cells. In tumors
with a higher cellular and genetic heterogeneity not fitting with
this simple model, AI could be detected but difficult to interpret in
the context of copy-number and percentage of AI-cells.
The re-analysis of 29 neurofibromas showed a good agreement
between the information generated by MMPA (copy-number
status; percentage of AI/non-AI cells in the tumor) and the data
generated in Garcia-Linares et al. (2011) using other standard
techniques such as MLPA, PRA and SNP-array analysis. MMPA
showed a high degree of sensitivity and accuracy. For the study of
neurofibromas and the MMPA setup described here, most
microsatellites (,82%) showing AI were correctly determining
the copy-number status and the AI-mechanism. ,15% of
microsatellites generated out of range values and thus, were finally
not used in the analysis. The number of microsatellites indicating
an incorrect AI-mechanism was very low (,2%). Considering
these data, using a criterion that allows the discrepancy of 1 AI-
microsatellite, for neurofibromas with at least 3 informative AI-
microsatellites (27/29) the MMPA analysis correctly determined
the AI-mechanism in all of them.
MMPA calculations provide the same type of information that
SNP-array analysis provides but at a much lower resolution. In
contrast to this limitation, the cost is also much lower and after a
brief PCR set up, it can be applied to any microsatellite multiplex
PCR reaction already developed in any standard molecular
biology lab. MMPA should be particularly useful for analyzing
specific regions of the genome containing tumor suppressor genes
causing cancer syndromes. Additionally it can be also used to scan
different loci scattered along the genome in large series of control-




All the human samples used in this study were provided by
patients who had given their written informed consent. The ethical
committee review board of the Bellvitge Hospital, Barcelona,
Spain, approved the study.
DNA extraction
DNA from blood was isolated either by the Wizard Genomic
DNA purification kit (Promega) according to the manufacturer’s
instructions or by the ‘‘salting out’’ method as described elsewhere
[17]. This DNA was used as control or reference DNA in the
allelic imbalance analysis of tumors of the respective patients.
Control DNA was also obtained in some cases from the skin of
patients (or derived fibroblasts). DNA from skin or neurofibromas
was extracted using the Gentra Puregene Kit (Qiagen) following
manufacturer’s instructions. Concentration, purity and quality of
the DNA were first assessed using a nanodrop spectrophotometer
and gel electrophoresis analysis. For an accurate quantification of
DNA concentration, samples were further quantified using Quant-
iT PicoGreen reagent (Invitrogen). All DNA samples were stored
and preserved at 4uC and at 280uC. Samples used in this study: a)
For the MMPA setting up samples are mentioned in Figures S1,
S2a and S8; b) For MMPA validation 29 pairs of control-
neurofibroma samples were used and are listed in Table 1.
Microsatellite Multiplex PCR analysis (MMPA)
We have used a previously developed multiplex PCR reaction
with the simultaneous amplification of 16 microsatellites ([13] and
Table S1). To set up new conditions for performing the proposed
MMPA calculations, we modified original PCR conditions
according to the parameters and quality controls explained in
the supplementary information. We used a Multiplex PCR Kit
(Qiagen) with which we obtained good global microsatellite
amplification, providing good peak heights and a robust band
pattern in the electropherogram readings. We adjusted the
concentrations of the different primer pairs to obtain similar
product yields of each of the different amplicons of the multiplex
PCR. The multiplex PCR reaction was carried out in a 25 ml
reaction, containing 80 ng of DNA. An initial cycle of denatur-
ation at 95uC for 15 min was followed by 22 cycles of:
denaturation at 94uC, annealing at 56uC and extension at 72uC
for 30 sec, 3 min and 1,5 min respectively. A final cycle at 60uC
for 30 min was performed. 2 ml of PCR product was mixed with
7,8 ml of formamide and 0,2 ml of size standard Liz500. PCR
fragments were separated by capillary electrophoresis on an ABI
3130xl Genetic Analyzer. Peak height values for each microsat-
ellite allele were extracted using Peak Scanner software (Applied
Table 2. MMPA validation for the % of non-AI cells.
Tumor samples MMPA (% non-AI cells) SNP-array (% non-AI cells) Difference between techniques (%)
P023-6N (Del) 40 42.5 2,5
P079-1N (Del) 66.1 66 0.1
P082-6N (Del) 57 65 8
P011-16N (HR) 67 74.9 7,9
P023-14N (HR) 45 59.5 14,5
P102-18N (HR) 43 47 4
P103-5N (HR) 44 50.6 6,6
P103-21N (HR) 56.1 55.7 0,4
P109-6N (HR) 46.2 53.6 7,4
Analysis of the percentage of non-AI cells present in 9 neurofibromas using newly developed MMPA calculations and comparison with data obtained applying GPHMM
algorithm to previously generated SNP-array data for the same tumors (13).
doi:10.1371/journal.pone.0042682.t002
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Biosystems). We used MMPA to analyze 29 control-neurofibroma
pairs of samples.
Semi-automated analysis of MMPA results
To analyze the data extracted by Peak Scanner software we
have developed a tool that automates all the necessary MMPA
calculations (Script S1). This automated analysis has been
implemented using the Ruby programming language in a script
named mmpa.rb. The script calculates and outputs the Km,
comparing the reactions of control-tumor pairs, the average
percentage of normal tissue contamination in the tumor, and the
overall mechanism of AI for the test sample. For each informative
microsatellite, calculated Ks, AI determination, observed peak
height ratios, expected peak height ratios, % of non-AI cells and
mechanisms generating the AIs are also calculated. mmpa.rb is
released under the GNU GPL license. Source code and detailed
instructions for its installation and use are available in Script S1
and can be also downloaded from http://www.imppc.org/
research-activities/genetic-variation-and-cancer/mmpa.html.
SNP-array data analysis
SNP-array data generated in a previous study [13] (Illumina
Infinium SNP-array, Human660W-Quad beadchip ,660000
SNPs) was used to determine the percentage of cells bearing AIs
by applying a Global Parameter Hidden Markov Model
(GPHMM) algorithm [16] that quantitatively models signal
baseline shift due to aneuploidy and also the presence of normal
diploid cells. Results were compared with MMPA calculations.
Supporting Information
Figure S1 All co-amplified microsatellites in the MMPA
reaction need to be analyzed when still in exponential
phase of amplification. To determine the optimal number of
cycles of the MMPA reaction, microsatellite amplification was
monitored from 19 to 26 cycles. Peak height intensities for the two
alleles of each microsatellite are plotted. This analysis was
performed in triplicate for sample P114-15N (only one reaction
is shown). We used 22 cycles for the MMPA technique exemplified
in this work.
(EPS)
Figure S2 (a) We estimated a limit CV value (s/Km) for the
MMPA reaction exemplified here by analyzing Km variation in
control microsatellites from four independent NF1 patients: 6
samples from patient P114, 4 samples from patient P027, 8 samples
from patient P024 and 8 samples from patient P013. Each blue dot
represents the CV of Km calculated for each pair of control samples
(using one sample per individual as a reference). Only heterozygous
microsatellites were used to calculate these ratios. As CV did not
differ more than 0.1 in all but 2 cases, we considered CV #0.15 an
optimal value for this MMPA reaction set up. (b) We performed an
analysis to study the individual microsatellite behavior of the
different co-amplified microsatellite markers in the MMPA
reaction, and to obtain a cut off value on Km dispersion (W). Figure
S2b shows the box-plots of 1-(K/Km), which measures the deviation
of K with respect to Km for each co-amplified microsatellite marker
allele. K/Km should be close to 1 in co-amplified microsatellites
behaving similarly. Control samples used were the same as those in
figure S2a, and values were generated for each pair of samples of the
different individuals (using 1 sample of each individual as a control
reference). For most microsatellite markers, K values didn’t differ
more than 12% from the Km value. We established W to be 0.12 in
our MMPA reaction set up.
(EPS)
Figure S3 We established a limit QAI value to determine
the presence or absence of AI in tumor samples by
analyzing the inherent variation of microsatellite allelic
ratios in control sample pairs (here QAI = RCont1/R Cont2)
using the expression 1-(QAI). Figure S3 shows box-plots of the
1-(QAI) values of all ratios obtained from heterozygous microsat-
ellites used in the exemplified MMPA reaction. For microsatellites
with no AI, QAI should be close to 1 if there is no variation
between allelic ratios. Control samples used were the same as those
in figure S2a (using 1 sample as a control reference). For control
samples with no AI, variation didn’t exceeded 0.1. We established
a limit QAI value of 0.2 to consider presence of AI.
(EPS)
Figure S4 Methodological limitations of MMPA provide
an inherent variation on Km values, as shown in Figure
S2. Figure S4 illustrates how variation on Km (by applying
different CVs) affects the calculation of the % of 2n cells present in
a tumor sample in a hypothetical reaction, for AI-microsatellites
with one observed allele peak height lower than expected (copy-
loss and copy-neutral events). In the presented hypothetical
scenario the parameters used are: a Km= 1; a microsatellite with
a control allele peak height of 1000 (fluorescence intensity); a
tumor peak height representing a % of 1000 (fluorescence
intensity) proportional to the % of non-AI cells present in the
tumor. Solid line: % of 2n cells for CV = 0. Dashed lines: % of 2n
cells for the different CVs applied. This figure shows that it is
important to set up MMPA reactions with a low degree of
variation on Km, since the greater the CV on Km the less accurate
is the calculation of the percentage of 2n cells in the tumor.
(EPS)
Figure S5 To determine the locus copy number of AI-
microsatellites, two different intervals of expected allele
peak height values are calculated, one for a copy-
number loss scenario and another considering a copy-
neutral event (see text for details and Figure 3). The
observed allele peak height will fit into one of the two expected
intervals. However, depending on the percentage of normal cells
present in the tumor and the W used, the two different intervals
can overlap, making it impossible to discern which is the
mechanism generating AI. Figure S5 shows at which percentage
of 2n cells these two intervals overlap for a hypothetical MMPA
reaction. The parameters used were: Km= 1, W= 0.12, control
peak height = 1000 (fluorescence intensity), tumor peak
height = 1000 for copy-loss (one copy of the locus) and 2000 for
copy-neutral (two copies of the locus). Blue and green lines define
the intervals (Km6e; e= Km?W) of expected allele peak height
values for copy-loss and copy-neutral mechanisms respectively,
under different percentages of 2n cells. This figure shows that the
lower the W of the MMPA reaction set up, the higher the
sensitivity for differentiating between copy-loss and copy-neutral
events. This is important when analyzing tumors with high
percentages of infiltrating normal cells.
(EPS)
Figure S6 (a) Schematic view of AIs generated by either single
allele locus amplification (copy-number gain), or by differential
amplification of both alleles (multiple amplification). Solid color
peaks represent allele peak heights obtained from microsatellite
electropherograms after a theoretical MMPA. Dashed color peaks
indicate expected peak heights (in the case 100% of the cells were
non-AI). A microsatellite marker with an AI generated by copy-
number gain will show one of the observed allele peak heights
higher than expected and the other one similar to its respective
expected peak height. A microsatellite marker with an AI
Rapid Genetic Analysis of Tumor Heterogeneity
PLOS ONE | www.plosone.org 8 August 2012 | Volume 7 | Issue 8 | e42682
generated by multiple differential amplifications will show both
observed allele peak heights higher than their expected peak
heights. In both scenarios there is no observed peak height lower
than expected. (b) Determination of allele locus copy-number for
the two scenarios described. Only allele peak heights higher than
expected will be used (Peak 1obs in copy-gain and Peak 1obs or
Peak 2obs for multiple amplification). In these cases, observed peak
height values will fall inside the interval of expected peak height
values [Peakexp cg (6e)] obtained by using the actual number of
copies of the locus, represented by the variable X. The percentage
of AI/non-AI cells used for these calculations will need to be
obtained from a different microsatellite marker showing AI
generated by either copy-loss or copy-neutral events.
(EPS)
Figure S7 MMPA Workflow.
(EPS)
Figure S8 We performed an assay to determine the
limit on the percentage of 2n cells present within tumor
samples at which MMPA calculations are still reliable
for the analysis of control/tumor pairs. The example
illustrates the case of an AI caused by a copy-loss. To reproduce
this situation two different DNA samples were mixed at different
proportions. One DNA was from a normal individual and the
other was from his son with Neurofibromatosis type 1 caused by a
deletion of the NF1 gene (maternal origin) and adjacent regions
(already characterized and published elsewhere). For all microsat-
ellites located within the deleted region the son was missing the
maternal allele and only the remaining paternal allele was present.
DNAs were mixed raging from proportions of 0% father’s DNA-
100% son’s DNA, to exactly the opposite (100% father’s DNA-0%
son’s DNA), in steps of 10% increasing proportions of father’s
DNA. Alleles from heterozygous markers, outside the deleted
region and shared by both father and son, were used as controls
since, independently of the DNA admixture, they were always
present in a 100% proportion (Figure S8c). To reproduce the
presence of normal cells within tumors, heterozygous paternal
alleles not present in the son and mapping within the deleted
region were quantified (see boxed alleles in Figure S8c). A control
sample with 100% father’s DNA was independently paired with
each of the different DNA admixtures. Km and the different
calculations were generated for each pair of samples. The real
percentages of DNA admixtures were compared to the calculated
percentages obtained by applying MMPA. Copy number analysis
and the mechanism generating AI was also determined. a) Results
(in triplicate) of the % of non-AI cells and the mechanism
generating AI obtained by applying an MMPA to the different
DNA admixtures. MMPA technique was able to calculate the
percentage of non-AI cells present in the DNA admixtures up to
70–80% while still detecting the presence of a deletion (see also
Figures S4 and S5). b) Regression analysis indicating a good
correlation between the real percentages of non-AI cells present in
the DNA admixtures and the percentages calculated by applying
MMPA. Blue dots represent the percentage of non-AI cells
calculated using MMPA of each replica vs. the real percentage of
non-AI cells. c) Examples of the electropherograms obtained for
control and AI microsatellites for the different DNA admixtures.
(EPS)
Table S1 Combination of primers used in the Micro-
satellite Multiplex PCR Assay exemplified in this work.
(EPS)
Script S1 Semi-automated analysis of MMPA results. In
order to facilitate the calculations of the MMPA assay, we
developed an automated analysis script that outputs the different
parameters of an MMPA reaction together with the different
calculations. Script S1 contains files required to perform the
MMPA analysis and a short Script guide.
(RAR)
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